Key Points
- Insider sale: Director Edward Md Kaye sold 1,066 shares on Dec. 2 at an average of $29.78 for proceeds of $31,745, leaving him with 52,375 shares (a 1.99% ownership decline).
- Earnings and trading: Stoke reported a quarterly EPS miss (–$0.65 vs. –$0.54 expected) but revenue beat ($10.63M vs. $6.06M), and the stock is trading around $30.58 with a $1.75B market cap and a 52‑week range of $5.35–$38.69.
- Analyst sentiment: Analysts are mostly bullish with a consensus "Buy" and an average target of $31, and several firms recently raised price targets (e.g., BTIG $39, Wedbush $32).
Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report) Director Edward Md Kaye sold 1,066 shares of the business's stock in a transaction on Tuesday, December 2nd. The shares were sold at an average price of $29.78, for a total transaction of $31,745.48. Following the completion of the sale, the director directly owned 52,375 shares in the company, valued at $1,559,727.50. This represents a 1.99% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
Stoke Therapeutics Trading Down 1.2%
Shares of NASDAQ STOK opened at $30.58 on Thursday. The company has a fifty day moving average price of $28.74 and a 200 day moving average price of $19.61. The firm has a market cap of $1.75 billion, a PE ratio of 45.53 and a beta of 1.14. Stoke Therapeutics, Inc. has a 1-year low of $5.35 and a 1-year high of $38.69.
Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last posted its quarterly earnings data on Tuesday, November 4th. The company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.54) by ($0.11). The firm had revenue of $10.63 million for the quarter, compared to analyst estimates of $6.06 million. Stoke Therapeutics had a return on equity of 13.28% and a net margin of 19.73%. Equities research analysts forecast that Stoke Therapeutics, Inc. will post -2.01 EPS for the current year.
Analyst Upgrades and Downgrades
A number of research firms recently weighed in on STOK. BTIG Research reaffirmed a "buy" rating and issued a $39.00 target price on shares of Stoke Therapeutics in a research report on Wednesday, November 5th. Wedbush increased their price target on Stoke Therapeutics from $22.00 to $32.00 and gave the company an "outperform" rating in a research report on Wednesday, November 5th. JPMorgan Chase & Co. upped their price objective on Stoke Therapeutics from $15.00 to $25.00 and gave the stock a "neutral" rating in a research note on Monday, November 3rd. Weiss Ratings reissued a "hold (c)" rating on shares of Stoke Therapeutics in a research note on Monday. Finally, Canaccord Genuity Group increased their price target on shares of Stoke Therapeutics from $24.00 to $28.00 and gave the company a "buy" rating in a research note on Wednesday, November 5th. Two analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and two have given a Hold rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Buy" and an average target price of $31.00.
View Our Latest Stock Analysis on Stoke Therapeutics
Hedge Funds Weigh In On Stoke Therapeutics
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Allspring Global Investments Holdings LLC bought a new position in shares of Stoke Therapeutics in the second quarter valued at about $402,000. Siren L.L.C. raised its holdings in Stoke Therapeutics by 12.4% in the 1st quarter. Siren L.L.C. now owns 2,247,347 shares of the company's stock valued at $14,945,000 after acquiring an additional 247,347 shares during the period. Aviva PLC acquired a new stake in Stoke Therapeutics during the second quarter worth approximately $499,000. KLP Kapitalforvaltning AS boosted its holdings in shares of Stoke Therapeutics by 131.6% during the second quarter. KLP Kapitalforvaltning AS now owns 13,200 shares of the company's stock worth $150,000 after acquiring an additional 7,500 shares during the period. Finally, Invesco Ltd. increased its stake in shares of Stoke Therapeutics by 117.0% during the first quarter. Invesco Ltd. now owns 26,183 shares of the company's stock worth $174,000 after purchasing an additional 14,118 shares during the period.
Stoke Therapeutics Company Profile
(
Get Free Report)
Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
